Tag: linker chemistry
Astellas Pharma and Sony Sign Collaborative Research Agreement for the Development...
Two unlikely partners, Sony Corporation ' Biotechnology devision and Astellas Pharma have signed a collaborative research agreement to discover and develop a novel Antibody-drug Conjugate (ADC) technology platform based on Sony's unique polymeric material called KIRAVIA™ Backbone.
A Superglue for ADCs: Connecting the Cytsteine Residues of a Tumor-sensing...
The Leibniz-Forschungsinstitut für Molekulare Pharmakologie (FMP) and the Ludwig-Maximilians-Universität München (LMU) hve developed an innovative technology designed to make it possible to treat cancer...
YProtech: Specialists in High Value Chemistries, from Early Research and Lead...
Established in 2011 YProtech is a leading Chemistry Services Contract Research Organization specializing in high value chemistry services.
The company offers niche chemistry based services...
Antibody Drug Conjugate Development: Keys to Rapid IND Submission and Approval
Antibody drug conjugates (ADCs) are a relatively new type of drug that combines the targeting ability of a biologic with a highly potent cytotoxic...
Preclinical Studies Show Significant Improved Therapeutic Index
Synaffix, a Netherlands-based biotechnology company exclusively focusing on the continued advancement of best-in-class and industry leading antibody-drug conjugate (ADC) technology platforms, has competed a new set...
Avacta and Glythera Partner to Develop Novel, Highly Targeted, Drugs
Avacta Life Sciences, the developer of Affimer® biotherapeutics and research reagents will collaborate with Glythera a developer of advanced, stable conjugation chemistries and novel, ultra-potent...
Linkers for Antibody Drug Conjugates: Current Role and Advancements
Advancements in research have shifted the way we think of combating cancer, and traditional treatment options are on the path to being replaced by...
Kairos and Zymeworks Bring Together Complementary Technologies for the Development of...
Zymeworks, a privately held biotherapeutics company developing best-in-class Azymetric™ bi-specific antibodies, multi-specific antibodies and antibody drug conjugates for the treatment of cancer, and Kairos Therapeutics,...
